Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with...

Industry: Biotechnology

Sector: Healthcare

Phone: 604-921-1810

Fax: 604-921-1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

DunkenInvest Oct. 24 at 2:57 PM

$BCTX bctx need to lock the fuck in. I wanna see them money fly 💸

0 · Reply

HyperGrowthStockLover Oct. 23 at 6:16 PM

$BCTX waiting on dilution before going in. My 2 cents.

1 · Reply

AceInTheHole18 Oct. 23 at 6:13 PM

$BCTX $FGEN game on!

0 · Reply

Dryrr Oct. 23 at 5:34 PM

$BCTX one more dilution and i might be interested again

0 · Reply

DunkenInvest Oct. 23 at 5:29 PM

$BCTX I was here chat🔥 Looking damn hot today

0 · Reply

ciggycapital Oct. 23 at 4:48 PM

$BCTX top chart on market imo

0 · Reply

ciggycapital Oct. 23 at 4:48 PM

$BCTX ready to launch

0 · Reply

DunkenInvest Oct. 23 at 4:37 PM

$BCTX Just waiting for the money to roll in 💰💷💶💴💵💸🪙

0 · Reply

Make_it_rain_2021 Oct. 22 at 9:04 PM

$BCTX looks the whole market took a kick to the teeth today!

1 · Reply

SmallCapGrowth Oct. 22 at 7:19 PM

All Day Stocks : $BCTX President and CEO, “Repeated conse... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176852388 via @Investors_Hub

0 · Reply

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Oct 21, 2025, 7:50 AM EDT - 3 days ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 3 days ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 4 days ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 11 days ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 21 days ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 2 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 2 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 2 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 2 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 3 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 3 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 3 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 3 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 3 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 3 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 3 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 3 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 3 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 3 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 3 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 4 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 4 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 5 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 5 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 5 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 5 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 5 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 6 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 6 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 7:30 AM EDT - 6 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 24, 2025, 8:00 PM EDT - 6 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 10:11 AM EDT - 6 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 7:30 AM EDT - 6 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 23, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 22, 2025, 7:30 AM EDT - 6 months ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 16, 2025, 7:30 AM EDT - 6 months ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 7 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Mar 20, 2025, 8:00 AM EDT - 7 months ago

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

Feb 5, 2025, 6:15 PM EST - 9 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Feb 5, 2025, 4:05 PM EST - 9 months ago

BriaCell Therapeutics Announces Closing of Public Offering

Feb 3, 2025, 7:59 PM EST - 9 months ago

BriaCell Therapeutics Announces Pricing of Public Offering

Feb 3, 2025, 4:45 PM EST - 9 months ago

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

Feb 3, 2025, 7:30 AM EST - 9 months ago

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Jan 27, 2025, 6:42 PM EST - 9 months ago

BriaCell Announces Completion of 15:1 Share Consolidation

Jan 3, 2025, 5:05 PM EST - 10 months ago

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

Dec 17, 2024, 4:05 PM EST - 11 months ago

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

Dec 17, 2024, 4:05 PM EST - 11 months ago

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

Dec 13, 2024, 4:05 PM EST - 11 months ago

BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

Dec 13, 2024, 7:50 AM EST - 11 months ago

BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

DunkenInvest Oct. 24 at 2:57 PM

$BCTX bctx need to lock the fuck in. I wanna see them money fly 💸

0 · Reply

HyperGrowthStockLover Oct. 23 at 6:16 PM

$BCTX waiting on dilution before going in. My 2 cents.

1 · Reply

AceInTheHole18 Oct. 23 at 6:13 PM

$BCTX $FGEN game on!

0 · Reply

Dryrr Oct. 23 at 5:34 PM

$BCTX one more dilution and i might be interested again

0 · Reply

DunkenInvest Oct. 23 at 5:29 PM

$BCTX I was here chat🔥 Looking damn hot today

0 · Reply

ciggycapital Oct. 23 at 4:48 PM

$BCTX top chart on market imo

0 · Reply

ciggycapital Oct. 23 at 4:48 PM

$BCTX ready to launch

0 · Reply

DunkenInvest Oct. 23 at 4:37 PM

$BCTX Just waiting for the money to roll in 💰💷💶💴💵💸🪙

0 · Reply

Make_it_rain_2021 Oct. 22 at 9:04 PM

$BCTX looks the whole market took a kick to the teeth today!

1 · Reply

SmallCapGrowth Oct. 22 at 7:19 PM

All Day Stocks : $BCTX President and CEO, “Repeated conse... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176852388 via @Investors_Hub

0 · Reply

SmallCapGrowth Oct. 22 at 6:58 PM

$BCTX receives its 4th consecutive - The Hunt for the Next 10 Bagger https://investorshangout.com/post/view?id=6797770

0 · Reply

ZacksResearch Oct. 22 at 6:25 PM

4th straight green light for $BCTX’s cancer trial 🚦 The DSMB again raised no safety concerns and recommended the pivotal phase III study of Bria-IMT plus CPI in metastatic breast cancer continue without changes — a strong vote of confidence in its safety profile. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-17204&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_17204

0 · Reply

DrevanTheStillblade Oct. 22 at 6:11 PM

GIPR is a hidden monster in the small‑cap world. Massively undervalued compared to what it holds—real estate assets over $91 M and trading near ~4.4 M float. No heavy borrow, minimal short interest (~1.4% of float). With a golden cross brewing, this could be the breakout engine many miss. $URGN $BLPH $TDAC $FCEL $BCTX

0 · Reply

JediGreen Oct. 22 at 5:00 PM

$BCTX

0 · Reply

JediGreen Oct. 22 at 4:58 PM

$BCTX BCTX Short Volume | ChartExchange https://chartexchange.com/symbol/nasdaq-bctx/short-volume/

0 · Reply

SmallCapGrowth Oct. 22 at 4:55 PM

All Day Stocks : $BCTX receives its 4th consecutive posit... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176851150 via @Investors_Hub

0 · Reply

SmallCapGrowth Oct. 22 at 4:33 PM

$BCTX announces that the independent Data Safety Monitoring Board (DSMB) has issued its fourth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI)... https://www.globenewswire.com/news-release/2025/10/22/3170997/0/en/BriaCell-Receives-Positive-Recommendation-from-Data-Safety-Monitoring-Board-DSMB-for-Phase-3-Study-in-Metastatic-Breast-Cancer.html

0 · Reply

SmallCapGrowth Oct. 22 at 4:06 PM

$BCTX receives its 4th consecutive positive DSMB recommendation for its Phase 3 study of Bria-IMT™ in metastatic breast cancer, with no safety concerns and the trial continuing without modification, showing confidence in Bria-IMT’s safety profile. https://globenewswire.com/news-release/2025/10/22/3170997/0/en/BriaCell-Receives-Positive-Recommendation-from-Data-Safety-Monitoring-Board-DSMB-for-Phase-3-Study-in-Metastatic-Breast-Cancer.html

0 · Reply

prismmarketview Oct. 22 at 3:49 PM

(NASDAQ: $BCTX) #BriaCellTherapeutics received its fourth consecutive positive safety review from the independent DSMB for its Phase 3 trial of Bria‑IMT™ combined with a checkpoint inhibitor in metastatic breast cancer. The board raised no safety concerns and advised the study continue unchanged under FDA Fast Track designation, reinforcing confidence in BriaCell’s safety profile. https://prismmarketview.com/briacells-phase-3-study-advances-with-fourth-consecutive-positive-safety-review/

0 · Reply

brd03 Oct. 22 at 3:46 PM

$BCTX The entire bio sector is down hugely past 2 days 🤷🏻‍♀️

0 · Reply

SmallCapGrowth Oct. 22 at 3:34 PM

Cancer Stock Alert: The Positive News Keeps Coming for $BCTX Phase 3 study is being conducted under FDA Fast Track Designation - Company addressing significant unmet need in metastatic breast cancer News: https://globenewswire.com/news-release/2025/10/22/3170997/0/en/BriaCell-Receives-Positive-Recommendation-from-Data-Safety-Monitoring-Board-DSMB-for-Phase-3-Study-in-Metastatic-Breast-Cancer.html

0 · Reply

DunkenInvest Oct. 22 at 2:58 PM

$BCTX I thought we were supposed to go BOOOM today 😬

0 · Reply

Market Cap	8.17M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	81,721
Avg Vol	88,670
Day's Range	N/A - N/A
Shares Out	678,000.00
Stochastic %K	61%
Beta	1.21
Analysts	Sell
Price Target	$40.00